Related Experiment Video
Updated: Jul 6, 2026
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Oleanolic acid enhances insulin secretion in pancreatic beta-cells
Tracy Teodoro1, Liling Zhang, Todd Alexander
1Toronto General Research Institute, University Health Network, Toronto, ON, Canada M5G1L7.
FEBS Letters
|March 28, 2008
Summary
Oleanolic acid, a natural compound, boosts insulin secretion and levels in pancreatic cells and islets. This suggests potential anti-diabetic benefits from this plant-derived triterpenoid.
Area of Science:
- Pharmacology
- Endocrinology
- Natural Products Chemistry
Background:
- Oleanolic acid is a plant-derived triterpenoid with potential therapeutic properties.
- Pancreatic beta-cells are crucial for insulin production and glucose regulation.
- Dysfunctional insulin secretion is a hallmark of diabetes mellitus.
Purpose of the Study:
- To investigate the effects of oleanolic acid on insulin secretion and content in pancreatic beta-cells and rat islets.
- To compare oleanolic acid's efficacy with known anti-diabetic agents.
- To explore the underlying mechanisms of oleanolic acid's action on insulin secretion.
Main Methods:
- Utilized INS-1 832/13 cell line and isolated rat islets for experiments.
- Assessed insulin secretion under basal and glucose-stimulated conditions.
- Measured intracellular calcium (Ca2+) and cyclic adenosine monophosphate (cAMP) levels.
- Quantified total cellular insulin protein and mRNA levels after chronic treatment.
Main Results:
- Oleanolic acid significantly enhanced insulin secretion in both cell lines and isolated islets.
- Its effects were comparable to tolbutamide and Exendin-4 under specific conditions.
- No significant changes in intracellular Ca2+ or cAMP were observed.
- Chronic oleanolic acid treatment increased insulin protein and mRNA levels.
Conclusions:
- Oleanolic acid effectively enhances insulin secretion and content in pancreatic beta-cells.
- These findings support the potential of oleanolic acid as a therapeutic agent for diabetes.
- The mechanism of action does not appear to involve direct modulation of Ca2+ or cAMP pathways.
Related Concept Videos
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...